MCID: PNC034
MIFTS: 56

Pancreas Disease

Categories: Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Pancreas Disease

Summaries for Pancreas Disease

Disease Ontology : 12 An endocrine system disease that is located in the pancreas.

MalaCards based summary : Pancreas Disease, also known as abnormality of the pancreas, is related to endocrine pancreas disease and acute pancreatitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Pancreas Disease is INS (Insulin), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Pancrelipase and Resveratrol have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and liver, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Related Diseases for Pancreas Disease

Diseases related to Pancreas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 142)
# Related Disease Score Top Affiliating Genes
1 endocrine pancreas disease 33.5 ABCC8 IGF1 INS LEP SST
2 acute pancreatitis 29.8 CCK SCT SPINK1 SST
3 pancreatitis 29.8 CCK PRSS1 SCT SPINK1 SST
4 pancreatic cancer 29.7 AREG CCK HRAS KRAS PRSS1 SCT
5 pancreas, annular 10.8
6 pancreatic agenesis 10.8
7 sigmoid neoplasm 10.4 HRAS KRAS
8 bronchus adenoma 10.4 POMC SST
9 bronchial adenomas/carcinoids childhood 10.4 POMC SST
10 gastrinoma 10.4 INS SCT SST
11 periampullary adenoma 10.4 HRAS KRAS SST
12 nasal cavity adenocarcinoma 10.4 CCK HRAS KRAS
13 pancreatic endocrine carcinoma 10.4 INS POMC SST
14 scleredema adultorum 10.3 INS POMC
15 type 1 diabetes mellitus 15 10.3 GCG HRAS INS
16 duodenum cancer 10.3 HRAS KRAS SST
17 secondary hypertrophic osteoarthropathy 10.3 HRAS KRAS POMC
18 acidophil adenoma 10.3 IGF1 POMC SST
19 duodenogastric reflux 10.3 CCK SCT SST
20 apocrine adenoma 10.3 HRAS KRAS
21 recurrent acute pancreatitis 10.3 PRSS1 SCT SPINK1
22 duodenal somatostatinoma 10.3 INS PPY SST
23 pituitary-dependent cushing's disease 10.3 INS POMC SST
24 pituitary infarct 10.3 IGF1 POMC SST
25 dyspepsia 10.3 CCK SST TRPV1
26 pain agnosia 10.3 CCK POMC TRPV1
27 sheehan syndrome 10.3 IGF1 INS POMC
28 agnosia 10.3 CCK POMC TRPV1
29 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 10.3 LEP POMC
30 pancreatic cystadenoma 10.3 GCG INS SST
31 colloid carcinoma of the pancreas 10.3 HRAS KRAS SMAD4
32 sick building syndrome 10.3 LEP POMC TRPV1
33 maturity-onset diabetes of the young, type 7 10.3 CCK INS SCT
34 functional gastric disease 10.3 CCK INS SST TRPV1
35 secondary adrenal insufficiency 10.3 IGF1 INS
36 hirata disease 10.3 ABCC8 GCG INS
37 biliary tract neoplasm 10.3 HRAS KRAS SMAD4
38 thyroid gland disease 10.3 INS POMC SST
39 exocrine pancreatic insufficiency 10.3 CCK SCT SPINK1
40 chiasmal syndrome 10.3 POMC SST
41 prostate adenoid cystic carcinoma 10.3 HRAS POMC
42 hyperinsulinemic hypoglycemia 10.3 ABCC8 INS SST
43 acute insulin response 10.3 ABCC8 GCG INS
44 mucinous lung adenocarcinoma 10.3 AREG HRAS KRAS
45 gallbladder disease 10.3 CCK INS KRAS SST
46 fetal erythroblastosis 10.3 INS POMC PPY
47 fetal macrosomia 10.3 IGF1 INS LEP
48 intestinal benign neoplasm 10.3 AREG HRAS KRAS
49 exanthem 10.3 AREG HRAS KRAS
50 diabetic neuropathy 10.3 INS LEP TRPV1

Graphical network of the top 20 diseases related to Pancreas Disease:



Diseases related to Pancreas Disease

Symptoms & Phenotypes for Pancreas Disease

UMLS symptoms related to Pancreas Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas, digestive system symptom

MGI Mouse Phenotypes related to Pancreas Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.18 ABCC8 AREG CCK DPP4 HRAS IGF1
2 growth/size/body region MP:0005378 10.18 AREG DPP4 HRAS IGF1 INS KRAS
3 homeostasis/metabolism MP:0005376 10.17 ABCC8 AREG CCK DPP4 HRAS IGF1
4 digestive/alimentary MP:0005381 10.03 AREG HRAS INS KRAS LEP SMAD4
5 integument MP:0010771 9.96 AREG HRAS IGF1 INS KRAS LEP
6 neoplasm MP:0002006 9.7 HRAS IGF1 KRAS LEP POMC SMAD4
7 no phenotypic analysis MP:0003012 9.61 ABCC8 CCK HRAS INS KRAS POMC
8 renal/urinary system MP:0005367 9.28 CCK HRAS IGF1 INS KRAS LEP

Drugs & Therapeutics for Pancreas Disease

Drugs for Pancreas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 967)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53608-75-6
2
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
3
Indomethacin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 53-86-1 3715
4
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838
5
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816
6
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
7 Nefopam Approved, Investigational Phase 4 13669-70-0
8
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 27203-92-5 33741
9
Ropivacaine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 84057-95-4 175805 71273
10
Sufentanil Approved, Investigational Phase 4,Not Applicable 56030-54-7 41693
11
Clonidine Approved Phase 4 4205-90-7 2803
12
Acetaminophen Approved Phase 4,Phase 1 103-90-2 1983
13
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
14
Meropenem Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 119478-56-7 64778 441130
15
Cefoperazone Approved, Investigational Phase 4 62893-19-0 44185
16
Metronidazole Approved Phase 4,Phase 1 443-48-1 4173
17
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 55-56-1 2713 9552079
18
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
19 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
20
Ivacaftor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 873054-44-5 16220172
21
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 32986-56-4 36294 5496
22
Ceftazidime Approved Phase 4,Phase 1,Not Applicable 78439-06-2, 72558-82-8 5481173
23
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-03-3
24
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
25
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-23-7 5754
26
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 437-38-7 3345
28
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 2078-54-8 4943
29
Diclofenac Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15307-86-5 3033
30
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
31
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1
32
Azithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 83905-01-5 55185 447043
33
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 1,Not Applicable 59467-70-8 4192
34
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
35
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9005-49-6
36
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 9005-49-6 772 46507594
37
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
38
Ketorolac Approved Phase 4,Phase 2,Phase 3,Phase 1 66635-83-4, 74103-06-3 3826
39
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33069-62-4 36314
40
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
41
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
42
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
43
Aztreonam Approved Phase 4,Phase 3,Phase 2,Not Applicable 78110-38-0 5362041 5742832
44
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6
45
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
46
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 148553-50-8 5486971
47
Oxycodone Approved, Illicit, Investigational Phase 4,Not Applicable 76-42-6 5284603
48
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
49
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
50
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838

Interventional clinical trials:

(show top 50) (show all 3717)
# Name Status NCT ID Phase Drugs
1 Effect of an Artificial Pancreas in Patients Undergoing Pancreatic Resection Unknown status NCT00661648 Phase 4
2 Oral Resveratrol to Prevent Post-ERCP Pancreatitis Unknown status NCT02947932 Phase 4 Resveratrol;Indomethacin
3 COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis Unknown status NCT02964403 Phase 4 Cox-2;Indomethacin
4 Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis Unknown status NCT02839356 Phase 4 epinephrine;normal saline
5 Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Severe Acute Pancreatitis Unknown status NCT02691598 Phase 4 Infusion
6 Epidural Analgesia for Pancreatitis (Epipan Study) Unknown status NCT02126332 Phase 4
7 Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis Unknown status NCT01992198 Phase 4 cefoperazone + metronidazole;Somatostatin;Meropenem
8 Comparative Study About the Impact of Two Oil Emulsions Administered Intravenously on Severe Acute Pancreatitis Unknown status NCT01376817 Phase 4 Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids;Fat emulsion with MCT and LCT
9 Prospective Random Comparing Study on EUS-guided Pseudocyst Drainage by Naso-pancreatic Tube and Stents Unknown status NCT01585662 Phase 4
10 Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy Unknown status NCT01070758 Phase 4 Lanreotide autogel
11 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
12 A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie Capsule Unknown status NCT02929420 Phase 4 Xiaoru Sanjie capsules;Xiao Yao pills
13 Impact of Immunonutrition on the Patients With Cystic Fibrosis Unknown status NCT02048592 Phase 4
14 CPET in CF Patients With One G551D Mutation Taking VX770 Unknown status NCT01937325 Phase 4 ivacaftor;placebo
15 Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis Unknown status NCT01044719 Phase 4 Ceftazidime;Tobramycin;Meropenem
16 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Unknown status NCT02775227 Phase 4 Hydrocortisone;Pasireotide
17 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
18 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
19 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
20 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
21 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
22 Alfentanil Versus Remifentanil in Patient-controlled Sedation During Endoscopic Retrograde Cholangiopancreatography (ERCP) Completed NCT01350037 Phase 4 alfentanil;remifentanil
23 Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
24 Imipenem Prophylaxis in Patients With Acute Pancreatitis Completed NCT02897206 Phase 4 Imipenem;Placebo
25 Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP) Completed NCT02111707 Phase 4 Rectal indomethacin 100mg one time before or after ERCP
26 Enteral Nutrition in Acute Pancreatitis Completed NCT01965873 Phase 4
27 Post ERCP Pancreatitis Prevention in Average Risk Patients Completed NCT01784445 Phase 4 Ceftazidime
28 Enzyme Suppletion in Exocrine Pancreatic Dysfunction Completed NCT01430234 Phase 4 Panzytrat 25.000 FIP-E units of Lipase
29 Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant Completed NCT01186562 Phase 4 Sitagliptin;Placebo
30 Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation Completed NCT01070680 Phase 4 Precedex;sodium chlorid 0,9%
31 Activated Protein C in Severe Acute Pancreatitis Completed NCT01017107 Phase 4 Activated protein C
32 Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube Completed NCT00999232 Phase 4 Erythromycin;Placebo
33 Early Enteral Nutrition for Severe Acute Pancreatitis Completed NCT00995098 Phase 4
34 Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis Completed NCT00957151 Phase 4 Creon
35 Acute Pancreatitis and Acute Fluid Collections Completed NCT00786929 Phase 4 Conservative treatment
36 Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients Completed NCT00560157 Phase 4
37 Creon After Pancreatic Surgery Completed NCT00535756 Phase 4 Creon;Placebo
38 Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis Completed NCT00318994 Phase 4 Meropenem
39 A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died Completed NCT00061438 Phase 4 meropenem
40 Prospective Study of Efficacy of Intra-muscular Vitamin D3 in Tropical Calcific Pancreatitis Completed NCT00956839 Phase 4 Vitamin D3 (Cholecalciferol)
41 Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy Completed NCT01550406 Phase 4
42 Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas Completed NCT01301222 Phase 4 Inj. Octreotide
43 Enteral Nutrition in the Treatment of Pancreatic Fistulas - A Prospective Study Completed NCT01025414 Phase 4 enteral nutrition;Parenteral nutrition
44 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study Completed NCT01744847 Phase 4
45 Electro Flo 5000 and Vest Therapy Completed NCT02277626 Phase 4
46 PTC Study to Evaluate Ataluren in Combination With Ivacaftor Completed NCT03256968 Phase 4 Ataluren
47 Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations Completed NCT03256799 Phase 4 Ivacaftor
48 A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Completed NCT02875366 Phase 4 LUM/IVA;Placebo
49 EASY: Extended Access to Sollpura Over Years Completed NCT02823964 Phase 4 Liprotamase
50 The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Completed NCT01507766 Phase 4 early enteral nutrition;Delayed enteral nutrition

Search NIH Clinical Center for Pancreas Disease

Genetic Tests for Pancreas Disease

Genetic tests related to Pancreas Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Pancreas 29

Anatomical Context for Pancreas Disease

MalaCards organs/tissues related to Pancreas Disease:

41
Pancreas, Lung, Liver, Heart, Kidney, Colon, Small Intestine

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreas Disease:

19
The Pancreas

Publications for Pancreas Disease

Articles related to Pancreas Disease:

(show top 50) (show all 82)
# Title Authors Year
1
Non-alcoholic fatty pancreas disease (NAFPD): A silent spectator or the fifth component of metabolic syndrome? A literature review. ( 29595117 )
2018
2
Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China. ( 29953011 )
2018
3
Use of Salmon Cardiac Primary Cultures (SCPCs) of different genotypes for comparative kinetics of mx expression, viral load and ultrastructure pathology, after infection with Salmon Pancreas Disease Virus (SPDV). ( 29102629 )
2018
4
A stochastic network-based model to simulate the spread of pancreas disease (PD) in the Norwegian salmon industry based on the observed vessel movements and seaway distance between marine farms. ( 30055856 )
2018
5
Transcriptome analyses of Atlantic salmon muscle genes induced by a DNA vaccine against salmonid alphavirus, the causative agent of salmon pancreas disease (PD). ( 30273392 )
2018
6
Increased dietary protein-to-lipid ratio improves survival during naturally occurring pancreas disease in Atlantic salmon, Salmo salar L. ( 30311660 )
2018
7
Effect of pancreas disease caused by SAV 2 on protein and fat digestion in Atlantic salmon. ( 30370677 )
2018
8
Non-alcoholic fatty pancreas disease as a risk factor for pancreatic cancer based on endoscopic ultrasound examination among pancreatic cancer patients: A single-center experience. ( 30483555 )
2018
9
Polycystic Pancreas Disease. ( 29287005 )
2017
10
Protein kinase STK25 aggravates the severity of non-alcoholic fatty pancreas disease in mice. ( 28442507 )
2017
11
The Burden of Systemic Adiposity on Pancreatic Disease: Acute Pancreatitis, Non-Alcoholic Fatty Pancreas Disease, and Pancreatic Cancer. ( 29491829 )
2017
12
Impact of non-alcoholic fatty pancreas disease on glucose metabolism. ( 28371475 )
2017
13
Non-alcoholic fatty pancreas disease. ( 28069746 )
2017
14
Experimental Piscine orthoreovirus infection mediates protection against pancreas disease in Atlantic salmon (Salmo salar). ( 27769313 )
2016
15
The epidemiological and economic effects from systematic depopulation of Norwegian marine salmon farms infected with pancreas disease virus. ( 27664454 )
2016
16
Ballan wrasse (Labrus bergylta Ascanius) is not susceptible to pancreas disease caused by salmonid alphavirus subtype 2 and 3. ( 27859355 )
2016
17
Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease. ( 27678349 )
2016
18
The epidemiology of pancreas disease in salmonid aquaculture: a summary of the current state of knowledge. ( 27136332 )
2016
19
Vaccination against pancreas disease in Atlantic salmon, Salmo salar L., reduces shedding of salmonid alphavirus. ( 27496170 )
2016
20
Mapping and validation of a major QTL affecting resistance to pancreas disease (salmonid alphavirus) in Atlantic salmon (Salmo salar). ( 25990876 )
2015
21
Comparison of transcriptomic responses to pancreas disease (PD) and heart and skeletal muscle inflammation (HSMI) in heart of Atlantic salmon (Salmo salar L). ( 26232631 )
2015
22
Xenopus as a Model for GI/Pancreas Disease. ( 26236566 )
2015
23
Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat. ( 26201937 )
2015
24
Space-time modelling of the spread of pancreas disease (PD) within and between Norwegian marine salmonid farms. ( 26104836 )
2015
25
Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. ( 26652175 )
2015
26
The economic benefits of disease triggered early harvest: A case study of pancreas disease in farmed Atlantic salmon from Norway. ( 26297077 )
2015
27
An experimental means of transmitting pancreas disease in Atlantic salmon Salmo salar L. fry in freshwater. ( 25297529 )
2014
28
Non-alcoholic fatty pancreas disease pathogenesis: a role for developmental programming and altered circadian rhythms. ( 24657938 )
2014
29
Cross-sectional study to investigate the presence of salmon pancreas disease virus in wild and feral fish populations in 10A lakes, Los Lagos Region, Chile. ( 24382013 )
2014
30
Serum enolase: a non-destructive biomarker of white skeletal myopathy during pancreas disease (PD) in Atlantic salmon Salmo salar L. ( 25168106 )
2014
31
Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients. ( 24974302 )
2014
32
Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population. ( 24572250 )
2014
33
Clinical manifestations of pancreas disease outbreaks in Norwegian marine salmon farming - variations due to salmonid alphavirus subtype. ( 24661057 )
2014
34
Transmission dynamics of pancreas disease (PD) in a Norwegian fjord: aspects of water transport, contact networks and infection pressure among salmon farms. ( 25254274 )
2014
35
Seasonal increase in sea temperature triggers pancreas disease outbreaks in Norwegian salmon farms. ( 23980568 )
2013
36
Immune parameters correlating with reduced susceptibility to pancreas disease in experimentally challenged Atlantic salmon (Salmo salar). ( 23306092 )
2013
37
The association between nonalcoholic fatty pancreas disease and diabetes. ( 23671610 )
2013
38
Transmission dynamics of pancreas disease (PD) in a Norwegian fjord: aspects of water transport, contact networks and infection pressure among salmon farms. ( 23452114 )
2013
39
Mortality related to pancreas disease in Norwegian farmed salmonid fish, Salmo salar L. and Oncorhynchus mykiss (Walbaum). ( 23311767 )
2013
40
Estimation of the reproduction number of salmon pancreas disease virus subtype 3 in homogeneously mixed populations of Norwegian farmed Atlantic salmon. ( 23810623 )
2013
41
Comparative cardiac pathological changes of Atlantic salmon (Salmo salar L.) affected with heart and skeletal muscle inflammation (HSMI), cardiomyopathy syndrome (CMS) and pancreas disease (PD). ( 23200434 )
2013
42
The serum proteome of Atlantic salmon, Salmo salar, during pancreas disease (PD) following infection with salmonid alphavirus subtype 3 (SAV3). ( 24145143 )
2013
43
Quality of raw and smoked fillets from clinically healthy Atlantic salmon, Salmo salar L., following an outbreak of pancreas disease (PD). ( 22924617 )
2012
44
Risk map and spatial determinants of pancreas disease in the marine phase of Norwegian Atlantic salmon farming sites. ( 23006469 )
2012
45
Detection of salmon pancreas disease virus in the faeces and mucus of Atlantic salmon, Salmo salar L., by real-time RT-PCR and cell culture following experimental challenge. ( 22924477 )
2012
46
Spleen-derived interleukin-10 downregulates the severity of high-fat diet-induced non-alcoholic fatty pancreas disease. ( 23285260 )
2012
47
Cohort study of effect of vaccination on pancreas disease in Norwegian salmon aquaculture. ( 23209075 )
2012
48
Formulations combining CpG containing oliogonucleotides and poly I:C enhance the magnitude of immune responses and protection against pancreas disease in Atlantic salmon. ( 21527278 )
2011
49
Maternal obesity programmes offspring development of non-alcoholic fatty pancreas disease. ( 20170634 )
2010
50
Pancreas disease (PD) in sea-reared Atlantic salmon, Salmo salar L., in Norway; a prospective, longitudinal study of disease development and agreement between diagnostic test results. ( 20609035 )
2010

Variations for Pancreas Disease

Expression for Pancreas Disease

Search GEO for disease gene expression data for Pancreas Disease.

Pathways for Pancreas Disease

Pathways related to Pancreas Disease according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 CCK GCG HRAS IGF1 INS KRAS
2
Show member pathways
13.4 CCK GCG LEP POMC PPY PRSS1
3
Show member pathways
12.63 AREG HRAS IGF1 INS KRAS SMAD4
4 12.62 AREG HRAS IGF1 INS KRAS
5
Show member pathways
12.37 HRAS IGF1 INS KRAS
6
Show member pathways
12.34 HRAS INS KRAS LEP
7
Show member pathways
12.28 HRAS IGF1 INS LEP
8
Show member pathways
11.97 HRAS IGF1 INS KRAS
9
Show member pathways
11.92 AREG HRAS IGF1 KRAS SMAD4
10 11.9 HRAS IGF1 KRAS SMAD4
11 11.77 HRAS KRAS SMAD4
12 11.58 HRAS IGF1 INS SMAD4
13 11.5 HRAS IGF1 KRAS
14
Show member pathways
11.49 HRAS IGF1 INS KRAS SMAD4
15
Show member pathways
11.45 DPP4 GCG LEP
16
Show member pathways
11.36 DPP4 GCG IGF1 INS LEP POMC
17 11.18 IGF1 INS KRAS
18 11.17 HRAS INS KRAS
19
Show member pathways
11.02 HRAS LEP POMC
20 10.97 HRAS KRAS SMAD4
21
Show member pathways
10.75 HRAS IGF1 KRAS
22 10.69 HRAS KRAS
23 10.38 CCK SCT

GO Terms for Pancreas Disease

Cellular components related to Pancreas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 CCK CELA1 DPP4 GCG IGF1 INS
2 extracellular space GO:0005615 9.47 AREG CCK CELA1 CELA3B GCG IGF1

Biological processes related to Pancreas Disease according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.89 AREG GCG HRAS IGF1 SMAD4
2 cell-cell signaling GO:0007267 9.87 AREG INS POMC SST
3 G protein-coupled receptor signaling pathway GO:0007186 9.86 AREG CCK GCG INS POMC PPY
4 female pregnancy GO:0007565 9.77 ABCC8 KRAS LEP
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.76 AREG CCK IGF1
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.73 IGF1 INS LEP
7 Ras protein signal transduction GO:0007265 9.71 HRAS IGF1 KRAS
8 positive regulation of MAPK cascade GO:0043410 9.67 HRAS IGF1 INS LEP
9 response to heat GO:0009408 9.65 IGF1 SST TRPV1
10 visual learning GO:0008542 9.63 ABCC8 CCK KRAS
11 response to pH GO:0009268 9.58 ABCC8 TRPV1
12 positive regulation of cell proliferation GO:0008284 9.56 AREG CCK DPP4 HRAS IGF1 INS
13 negative regulation of appetite GO:0032099 9.55 CCK LEP
14 response to isolation stress GO:0035900 9.52 HRAS KRAS
15 positive regulation of follicle-stimulating hormone secretion GO:0046881 9.51 LEP SMAD4
16 digestion GO:0007586 9.5 CCK PRSS1 SST
17 regulation of insulin secretion GO:0050796 9.46 ABCC8 DPP4 GCG LEP
18 bone mineralization involved in bone maturation GO:0035630 9.43 IGF1 LEP
19 positive regulation of luteinizing hormone secretion GO:0033686 9.4 LEP SMAD4
20 regulation of signaling receptor activity GO:0010469 9.32 AREG CCK GCG IGF1 INS LEP

Molecular functions related to Pancreas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.67 CELA1 CELA3B DPP4 PRSS1
2 signaling receptor binding GO:0005102 9.55 DPP4 GCG LEP POMC SCT
3 G protein-coupled receptor binding GO:0001664 9.43 POMC PPY SCT
4 peptide hormone receptor binding GO:0051428 9.32 CCK LEP
5 hormone activity GO:0005179 9.28 CCK GCG IGF1 INS LEP POMC
6 serine-type peptidase activity GO:0008236 9.26 CELA1 CELA3B DPP4 PRSS1

Sources for Pancreas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....